Amondys 45 Market Report 2026

Amondys 45 Market Overview

• The Amondys 45 market growth in the historic period has been driven by limited dmd treatment options, orphan drug incentives • Market expansion is supported by advancements in gene-based therapies, broader newborn screening • Growth Driver: Impact Of Rising Prevalence Of Genetic Disorders On The Growth Of The Amondys 45 Market • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Amondys 45 Market?

Amondys 45 (casimersen) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of duchenne muscular dystrophy (DMD) in patients with a confirmed mutation in the DMD gene that is amenable to exon 45 skipping. It is an antisense oligonucleotide therapy that works by targeting and skipping exon 45 during gene transcription, promoting the production of a functional, albeit shortened, dystrophin protein. The main indications in amondys 45 are duchenne muscular dystrophy (DMD)-exon 45 mutation and other genetic mutations. Duchenne muscular dystrophy (DMD) exon 45 mutation is a genetic form of DMD caused by a mutation in the DMD gene that affects exon 45, leading to a deficiency of dystrophin protein essential for muscle cell integrity and function. The users of this include adults, geriatric patients, and pediatric patients. It is distributed through various channels, such as hospitals, retail pharmacies, and online pharmacies.

What Is The Amondys 45 Market Growth Forecast?

The growth in the forecast period can be attributed to advancements in gene-based therapies, broader newborn screening, expansion of exon-specific drugs, sustained regulatory fast tracking, increasing clinical trial investments. Major trends in the forecast period include growth of exon skipping therapies, expansion of precision genetic medicine, increased focus on rare neuromuscular disorders, early diagnosis driven targeted treatments, rising regulatory support for orphan drugs.

Global Amondys 45 Market Segmentation

1) By Indication: Duchenne Muscular Dystrophy (DMD) – Exon 45 Mutation, Other Genetic Mutations 2) By End-User: Adult, Geriatric, Pediatric 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Are The Drivers Of The Amondys 45 Market?

The rise in the prevalence of genetic disorders is expected to propel the amondys 45 market going forward. A genetic disorder is a health condition caused by abnormalities in an individual's DNA, which can result from mutations in single or multiple genes, chromosomal changes, or a combination of genetic and environmental factors. The rising prevalence of genetic diseases is due to increased awareness and advancements in diagnostic technologies, as these enable earlier and more accurate detection of previously undiagnosed conditions. Amondys 45 aids in managing genetic disorders by targeting specific dystrophin gene mutations, making it effective for patients with Duchenne muscular dystrophy who require exon 45 skipping. It supports improved muscle function by enabling the production of a functional, though shorter, dystrophin protein, helping slow disease progression and enhance clinical outcomes. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,788 patients living with hereditary haemophilia A (HMA) in 2023–2024, up from 2,681 patients in 2022–2023. Therefore, the growing availability of genetic testing is driving the expansion of the amondys 45 industry. The rise in healthcare expenditure is expected to propel the growth of the amondys 45 market going forward. Healthcare expenditure refers to the total amount of financial resources spent on healthcare services, including medical treatment, infrastructure, and healthcare programs. The rise in healthcare expenditure is driven by several interconnected factors, including an aging population, advancements in medical technology, an increase in chronic diseases, inflation and rising costs of medical supplies, and higher expectations and demand for quality care. Amondys 45 contributes to the rise in healthcare expenditure by providing a specialized, targeted treatment for Duchenne muscular dystrophy, which, while improving patient outcomes, requires significant investment in advanced therapies and ongoing healthcare services. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Therefore, the rise in healthcare expenditure is driving the growth of the amondys 45 industry. The rising demand for personalized medicine is expected to propel the growth of the amondys 45 market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable the precise identification of genetic variations and tailored treatments for individuals. Amondys 45 enhances personalized medicine by providing a mutation-specific treatment approach tailored to patients with Duchenne muscular dystrophy who have genetic mutations amenable to exon 45 skipping. It delivers targeted therapeutic action, improving treatment precision and supporting better clinical outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the amondys 45 industry.

Key Players In The Global Amondys 45 Market

Major companies operating in the amondys 45 market are Sarepta Therapeutics Inc.

Regional Insights

North America was the largest region in the amondys 45 market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Amondys 45 Market?

The amondys 45 market consists of sales of injectable solutions and antisense oligonucleotide products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Amondys 45 Market Report 2026?

The amondys 45 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the amondys 45 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.